Latest Breaking News On - Accuron technology - Page 1 : comparemela.com

Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy.

Hong kongUnited statesLepu biopharmaFosun celregenFosun pharmaWorg pharmaGreater bay area fundLepu medical technologySingapore advanced medtech holdingsAccuron technologySwiss exchangeFosun health capital new drug fundUs treasury committee on foreign investmentShanghai roche acceleratorGlobal depositary receiptsCelregen therapeutics